期刊文献+

含莫西沙星方案治疗耐多药肺结核临床疗效观察 被引量:46

下载PDF
导出
摘要 目的探讨含莫西沙星方案治疗耐多药肺结核(MDR-PTB)的临床疗效。方法 MDR-PTB患者64例,随机分为治疗组和对照组,各32例。两组患者均予18个月的抗结核药物治疗。治疗组以莫西沙星联合帕司烟肼、利福喷丁、吡嗪酰胺、丙硫异烟胺、对氨基水杨酸、阿米卡星治疗3个月后,再以莫西沙星、帕司烟肼、利福喷丁、吡嗪酰胺、丙硫异烟胺治疗6个月,最后给予莫西沙星、帕司烟肼、利福喷丁、吡嗪酰胺治疗9个月;对照组除将莫西沙星替换为左氧氟沙星外,联合用药情况及治疗时间均与治疗组一致。观察两组患者痰菌转阴情况、X线病灶吸收率、结核空洞改善率及药物不良反应(ADR)发生情况。结果治疗组痰菌转阴率、X线病灶吸收率及结核空洞改善率分别为84.4%、87.5%和82.6%,均高于对照组的71.9%、75%、72.7%(P均<0.05);治疗组与对照组ADR发生率分别为18.8%、25.0%,差异无统计学意义(P>0.05)。结论含莫西沙星方案治疗MDR-PTB疗效优于含左氧氟沙星方案,且应用安全。
出处 《山东医药》 CAS 2013年第14期79-81,共3页 Shandong Medical Journal
  • 相关文献

参考文献12

  • 1Radhakrishna S. Contributions of the tuberculosis research centre, chennai in the field of epidemiology of tuberculosis ( a review over 50 years) [J]. Indian J Tuberc,2012,59(2) : 68-77.
  • 2赵伟杰,李芃,陆宇.莫西沙星与左氧氟沙星对结核分枝杆菌的交叉耐药性研究[J].中国防痨杂志,2009,31(8):469-472. 被引量:24
  • 3Cieri E, Lenti M, De Rango P, et al. Functional ability in patients with critical limb ischaemia is unaffected by successful revascular- ization [ J ]. Eur J Vasc Endovasc Surg, 2011,41 (2) :256-263.
  • 4Stevenson CR, Forouhi NG, Roglic G, et al. Diabetes and tuber- culosis: the impact of the diabetes epidemic on tuberculosis inci- dence[J]. BMC Public Health, 2007,7:234.
  • 5Dattilo PB, Casserly IP. Critical limb ischemia: endovascular strat- egies for limb salvage [ J]. Prog Cardiovasc Dis, 2011,54 ( 1 ) :47- 60.
  • 6高微微.如何早期发现耐药肺结核[J].结核病健康教育,2007(1):34-36. 被引量:10
  • 7蒋晓磊,崔玉彬,曹胜华.喹诺酮类抗菌药物研究新进展[J].中国抗生素杂志,2011,36(4):255-263. 被引量:31
  • 8Hu Y, Coates ARM, Mitchison DA. Sterilizing activities of fluoro- quinolones against rifampin-tolerant populations of mycobacterium tuberculosis [ J ]. Antimicrob Agents Chemother, 2003,47 ( 2 ) : 653-657.
  • 9Miyazaki E, Miyazaki M, Chen JM, et al. Moxifloxacin (BAY12- 8039) , a new 8-methoxyquinolone, is active in a mouse model oftuberculosis [ J]. Antimicrob Agents Chemother, 1999,43 ( 1 ) : 85 -89.
  • 10Fattorini L, Tan D, Iona E, et al. Activities of moxifloxacin alone and in combination with other antimicrobial agents against multi- drug-resistant mycobacterium tuberculosis infection in BALB/c mice [ J ]. Antimicrob Agents Chemothera, 2003,47 ( 1 ) : 360- 362.

二级参考文献45

  • 1安慧茹,王巍,王天昊,何珂,刘真,李素梅.结核分支杆菌喹诺酮耐药基因的研究[J].医学临床研究,2005,22(1):23-25. 被引量:4
  • 2周伟澄,周后元.氟喹诺酮类抗菌药物研究进展[J].中国医药工业杂志,2005,36(5):309-312. 被引量:18
  • 3蒋国军,苗智如,陈金文.第四代氟喹诺酮类抗菌药物的研究进展[J].浙江临床医学,2005,7(11):1201-1202. 被引量:5
  • 4世界卫生组织.耐药结核病规划管理指南[M].WHO/HTM/TB/2006:361.
  • 5Takiff HE, Salazar L, Guerrero C, Philipp W, Huang WM, Kreiswirth B, Cole ST, Jaeobs WR Jr, Telenti A. Cloning and Nucleotide Sequence of Mycobacterium tuberculosis gyrA and gyrB and Detection of Quinolone Resistance Mutations[J]. Antimicrob Agents Chemother, 1994,38(4) : 773-- 780.
  • 6萨姆布鲁克.分子克隆实验指导(第二版)[M].北京:科学出版社,1998:955.
  • 7Rodriguez JC, Cebrian L, Lopez M, Royo G. Mutant prevention concentration: comparison of fluoquinolones and linezolid with Mycobacterium tuberculosis[J]. J Antimicrob Chemother, 2004, 53(2) :441--444.
  • 8Guillemin I, Cambau E, Jarlier V. Sequences of Conserved Region in the A Subunit of DNA Gyrase from Nine Speeies of the genus Mycobaeterium: phylogenetic analysis and implication for intrinsic susceptibility to quinolones [J]. Antimierob Agents Chemother, 1995,39(9) :2145--2149.
  • 9Ginsburg AS, Sun R, Calamita H, Scott CP, Bishai WR, Grosset JH. Emergence of fluoroquinolone resistance in Mycobacterium tuberculosis during continuously dosed moxifloxacin monotherapy in a mouse model[J]. Antimicrob Agents Chemother, 2005,49 (9) : 3977-- 3979.
  • 10Onodera Y, Tanaka M, Sato K. Inhibitory activity of quinolones against DNA gyrase of Mycobacterium tuberculosis[J]. J Antimicrob Chemother, 2001,47(4) :447--450.

共引文献102

同被引文献237

引证文献46

二级引证文献366

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部